SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lawrence JS. Rheumatism in populations. London: William Heinemann Medical Books; 1997.
  • 2
    Gough AKS, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: 237.
  • 3
    Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R, et al. The acute phase and function in early rheumatoid arthritis: C-reactive protein levels correlate with functional outcome. J Rheumatol 1997; 24: 913.
  • 4
    Van Leeuwen MA, van Rijswijk MH, van der Heijde DMFM, Te Meerman GJ, van Riel PLCM, Houtman PM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993; 32 Suppl 3: 913.
  • 5
    Van der Heide A, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996; 124: 699707.
  • 6
    Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 220813.
  • 7
    Stenger AAME, van Leeuwen MA, Houtman PM, Bruyn GAW, Speerstra F, Barendsen BC, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37: 115763.
  • 8
    Ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM, et al. Randomised placebo-controlled study of stopping second-line agents in rheumatoid arthritis. Lancet 1996; 347: 34752.
  • 9
    Farr M, Bacon PA. How and when should combination therapy be used? The role of an anchor drug. Br J Rheumatol 1995; 34 Suppl 2: 1003.
  • 10
    Ferraccioli GF, Bartoli E. Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis. Clin Exp Rheumatol 1998; 16: 6626.
  • 11
    Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 195160.
  • 12
    Richardson C, Emery P. Clinical use of cyclosporin in rheumatoid arthritis. Drugs 1995; 50: 2636.
  • 13
    Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al, for the Methotrexate-Cyclosporine Combination Study Group. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 13741.
  • 14
    Stein CM, Pincus T, Yocum D, Tugwell P, Wells G, Gluck O, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. Arthritis Rheum 1997; 40: 184351.
  • 15
    Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis: the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 1426.
  • 16
    Kirwan J, Hickling P, Jacoby R. Joint destruction recommences after glucocorticoids are withdrawn in early rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S218.
  • 17
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.
  • 18
    Green MJ, Wakefield RJ, Proudman S, Marzo H, Conaghan P, Emery P. Outcome in oligoarthritis patients treated with IA corticosteroids to all clinically active joints [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S315.
  • 19
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 20
    Emery P. Prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol 1997; 24: 143642.
  • 21
    Van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31: 51925.
  • 22
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 23
    Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 130815.
  • 24
    Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 25
    Van der Heijde DMFM. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26: 7435.
  • 26
    Furst DE. Considerations on measuring decreased inflammatory synovitis. ILAR Bull 1994; 2: 1721.
  • 27
    Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998; 37: 6129.
  • 28
    Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA–DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991; 34: 1094105.
  • 29
    Chikanza LC, Panayi GS. The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin-2 and -4 production in corticosteroid sensitive and resistant subjects. Eur J Clin Invest 1993; 23: 84550.
  • 30
    Youssef PP, Triantafillou S, Parker A, Coleman M, Roberts-Thomson PJ, Ahern MJ, et al. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis: reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum 1996; 39: 19709.
  • 31
    Kadioglu A, Sheldon P. Steroid pulse therapy for rheumatoid arthritis: effect on lymphocyte subsets and mononuclear cell adhesion. Br J Rheumatol 1998; 37: 2826.
  • 32
    Matthews N, Emery P, Pilling P, Akbar A, Salmon M. Subpopulations of primed T helper cells in rheumatoid arthritis. Arthritis Rheum 1993; 36: 6037.
  • 33
    Elliott JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 1984; 226: 143941.
  • 34
    Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37: 5028.
  • 35
    Førre Ø, and the Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994; 37: 150612.
  • 36
    Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 100615.
  • 37
    Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, Førre Ø, Geidel H, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998; 37: 87482.
  • 38
    Landewé RBM, Goei Thè HS, van Rijthoven AWAM, Breedveld FC, Dijkmans BAC. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37: 63743.
  • 39
    González-Gay MA, Blanco R, García-Porrúa C, Ibáñez D, Vázquez-Caruncho M, Sánchez-Bursón J, et al. Long-term followup of patients receiving combined therapy with cyclosporine and methotrexate [letter]. Arthritis Rheum 1998; 41: 17034.
  • 40
    Soden M, Rooney M, Cullen A, Whelan A, Feighery C, Bresnihan B. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Br J Rheumatol 1989; 28: 28792.
  • 41
    Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998; 37: 9306.
  • 42
    Panayi GS, Tugwell P. The use of cyclosporin A in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol 1994; 33: 9679.